Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Quality of Life Research
Published in: Quality of Life Research 3/2015

Open Access 01-03-2015

Mapping FACT-P to EQ-5D in a large cross-sectional study of metastatic castration-resistant prostate cancer patients

Authors: J. Diels, P. Hamberg, D. Ford, P. Wheatley Price, M. Spencer, R. N. Dass

Published in: Quality of Life Research | Issue 3/2015

Login to get access

Abstract

Purpose

To construct a model to predict preference-adjusted EuroQol 5D (EQ-5D) health utilities for patients with metastatic castrate-resistant prostate cancer (mCRPC) using the disease-specific health-related quality of life (HRQoL) measure, functional assessment of cancer therapy-prostate (FACT-P).

Methods

HRQoL data were collected from patients with mCRPC who were enrolled in an observational study conducted in 47 centers across six European Union countries. Utility values were generated using a UK-specific EQ-5D value set. The predictive validity of the five FACT-P subscales, patient demographics, comorbidities and prior chemotherapy was tested using ordinary least squares (OLS), median, Gamma and Tobit multivariate regression models.

Results

FACT-P and EQ-5D questionnaires were completed by 602 (86 %) patients. Mean age [standard deviation (SD)] was 72.1 (7.9) years, mean time from diagnosis (SD) was 5.4 (4.4) years, and mean time since failure of androgen deprivation therapy (SD) was 1.0 (1.6) years. At study inclusion, 39 % of patients were chemotherapy-naïve, 37 % were undergoing chemotherapy, and 24 % were post-chemotherapy. Mean FACT-P and EQ-5D utility values were 104 and 0.66, respectively. OLS regression was the best-performing model, explaining 61.2 % of the observed EQ-5D variation. All FACT-P subscales were significantly predictive; the physical and functional well-being subscales had the highest explanatory value (coefficient 0.023 and 0.001, respectively, p < 0.0001). The other variables did not add additional explanatory value.

Conclusions

The algorithm developed enables translation of cancer-specific HRQoL measures to preference-adjusted health status in patients with mCRPC. The function may be useful in calculating EQ-5D scores when EQ-5D data have not been gathered directly.
Literature
1.
Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J. W., Comber, H., et al. (2013). Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. European Journal of Cancer, 49(6), 1374–1403.CrossRefPubMed
2.
Luengo-Fernandez, R., Leal, J., Sullivan, R. Economic burden of malignant neoplasms in the European Union. ESMO 2012, Vienna, Austria 2012; Poster 1415.
3.
Harris, W. P., Mostaghel, E. A., Nelson, P. S., & Montgomery, B. (2009). Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nature Clinical Practice Urology, 6(2), 76–85.CrossRefPubMedCentralPubMed
4.
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., et al. (2013). Abiraterone in metastatic prostate cancer without previous chemotherapy. New England Journal of Medicine, 368(2), 138–148.CrossRefPubMedCentralPubMed
5.
Sandblom, G., Carlsson, P., Sennfalt, K., & Varenhorst, E. (2004). A population-based study of pain and quality of life during the year before death in men with prostate cancer. British Journal of Cancer, 90(6), 1163–1168.CrossRefPubMedCentralPubMed
6.
7.
Scher, H. I., Morris, M. J., Kelly, W. K., Schwartz, L. H., & Heller, G. (2005). Prostate cancer clinical trial end points: “RECIST”ing a step backwards. Clinical Cancer Research, 11(14), 5223–5232.CrossRefPubMedCentralPubMed
8.
9.
Brozek, J. L., Kraft, M., Krishnan, J. A., Cloutier, M. M., Lazarus, S. C., Li, J. T., et al. (2012). Long-acting beta2-agonist step-off in patients with controlled asthma. Archives of Internal Medicine, 172(18), 1365–1375.CrossRefPubMed
10.
Dakin, H. (2013). Review of studies mapping from quality of life or clinical measures to EQ-5D: an online database. Health and Quality of Life Outcomes, 11(1), 151.CrossRefPubMedCentralPubMed
11.
Wu, E. Q., Mulani, P., Farrell, M. H., & Sleep, D. (2007). Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 10(5), 408–414.CrossRef
12.
Cella, D., Proskorovsky, I., Pan, F. (2012). Approach to fixing the discrepancy found in the Wu et al. FACT-P to EQ-5D questionnaire mapping algorithm. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 15(5), 783-784; author reply 785.
13.
Wu, C. H. (2012). Approach to Fixing the Discrepancy Found in the Wu et al. FACT-P to EQ5D Mapping Algorithm—Reply to Letter to the Editor by David Cella, Irina Proskorovsky, and Feng Pan. Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 15, 785.
14.
Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K. J. (1997). Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology, 50(6), 920–928.CrossRefPubMed
15.
Brazier, J. E., Yang, Y., Tsuchiya, A., & Rowen, D. L. (2010). A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. The European Journal of Health Economics, 11(2), 215–225.CrossRefPubMed
16.
Rowen, D., Brazier, J., & Roberts, J. (2009). Mapping SF-36 onto the EQ-5D index: How reliable is the relationship? Health Quality Life Outcomes, 7, 27.CrossRef
17.
Nelson, H. S., Weiss, S. T., Bleecker, E. R., Yancey, S. W., Dorinsky, P. M., & Group, S. S. (2006). The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest, 129(1), 15–26.CrossRefPubMed
18.
Austin, P. C. (2002). A comparison of methods for analyzing health-related quality-of-life measures. Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 5(4), 329–337.CrossRef
19.
McTaggart-Cowan, H., Teckle, P., & Peacock, S. (2013). Mapping utilities from cancer-specific health-related quality of life instruments: A review of the literature. Expert Review Pharmacoecon Outcomes Research, 13(6), 753–765.CrossRef
20.
Fayers, P. M., & Hays, R. D. (2014). Should linking replace regression when mapping from profile-based measures to preference-based measures? Value Health, 17(2), 261–265.CrossRefPubMedCentralPubMed
21.
Kim, E. J., Ko, S. K., & Kang, H. Y. (2012). Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients. Quality of Life Research, 21(7), 1193–1203.CrossRefPubMed
22.
Kim, S. H., Jo, M. W., Kim, H. J., & Ahn, J. H. (2012). Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients. Health Quality Life Outcomes, 10, 151.CrossRef
23.
Versteegh, M. M., Rowen, D., Brazier, J. E., & Stolk, E. A. (2010). Mapping onto EQ-5D for patients in poor health. Health Quality Life Outcomes, 8, 141.CrossRef
Metadata
Title
Mapping FACT-P to EQ-5D in a large cross-sectional study of metastatic castration-resistant prostate cancer patients
Authors
J. Diels
P. Hamberg
D. Ford
P. Wheatley Price
M. Spencer
R. N. Dass
Publication date
01-03-2015
Publisher
Springer International Publishing
Published in
Quality of Life Research / Issue 3/2015
Print ISSN: 0962-9343
Electronic ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-014-0794-5

Other articles of this Issue 3/2015

Quality of Life Research 3/2015 Go to the issue

OriginalPaper

Quality of life and socio-dental impact among underprivileged Brazilian adolescents

OriginalPaper

Cross-cultural validity of the thyroid-specific quality-of-life patient-reported outcome measure, ThyPRO

Response Shift and Missing Data

RespOnse Shift ALgorithm in Item response theory (ROSALI) for response shift detection with missing data in longitudinal patient-reported outcome studies

Review

Quality of life and dietary changes among cancer patients: a systematic review

OriginalPaper

Cross-cultural adaptation and validation of the Neck Bournemouth Questionnaire in the Italian population

OriginalPaper

Creating meaningful cut-scores for Neuro-QOL measures of fatigue, physical functioning, and sleep disturbance using standard setting with patients and providers